Abstract
Initiation of pharmacologic chaperone therapy for Fabry disease in the Canadian Fabry Disease Initiative (CFDI) registry is not associated with reduction of kidney function
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
